Immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
1. A composition comprising at least one isolated and purified immunogenic protein comprising any of even numbered SEQ ID NOS: 62-66.
2. The composition of claim 1 , wherein the at least one protein has a molecular weight of about 26,000-30,000 daltons as measured by mass spectroscopy.
3. The composition of claim 1 , wherein the at least one protein has a molecular weight of about 28-35 kDa as measured on a 10%-20% SDS polyacrylamide gel.
4. The composition of claim 1 , wherein said composition additionally comprises a pharmaceutically acceptable buffer, diluent, adjuvant or carrier.
5. The composition of claim 1 , wherein said composition additionally comprises a carrier.
6. The composition of claim 1 , wherein said composition additionally comprises an adjuvant.
7. The composition of claim 6 , wherein said adjuvant comprises a liquid.
8. The composition of claim 1 , wherein the at least one protein is non-lipidated.
9. The composition of claim 1 , wherein the at least one protein is a recombinant protein.
10. The composition of claim 1 , wherein the at least one protein is isolated from native Neisseria species.
11. The composition of claim 1 , wherein the at least one protein is a lipoprotein.
12. The composition of claim 1 , wherein the composition additionally comprises at least one Neisseria meningitidis Por A protein.
13. The composition of claim 1 , wherein the composition additionally comprises at least one additional surface antigen of Neisseria species, said additional surface antigen being a non-ORF2086 protein.
14. The composition of claim 1 , wherein said composition additionally comprises a polysaccharide.
15. The composition of claim 1 additionally comprising at least one protein comprising the amino acid sequence of any of even numbered SEQ ID NOS: 176-180 or 236-246.
16. The composition of claim 1 , wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 2-12.
17. The composition of claim 1 , wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 14-24.
18. The composition of claim 1 , wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 32-42.
19. The composition of claim 1 , wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 122-126.
20. The composition of claim 1 , wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 146-150.
21. The composition of claim 1 , wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 158-168.
22. The composition of claim 1 , wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 236-246.
23. A method of inducing an immune response in a mammal comprising administering to the mammal an effective amount of the composition of claim 1 .
24. The method of claim 23 , wherein said composition is administered parenterally.
25. The method of claim 23 , wherein said composition is administered mucosally.